AUS
NZ
UK
CA
USA
IND
Immunome Inc. announced that Horn Kinney, its Chief Business Officer, was awarded a substantial equity package on July 23, 2026, including 31,250 restricted stock units (RSUs) and 62,500 stock options. This equity grant aligns executive compensation with long-term shareholder value. The transaction was reported to the Securities and Exchange Commission on July 27, 2026, marking a significant increase in Kinney’s beneficial ownership in the NASDAQ-listed biopharmaceutical company.
Key Points
- NASDAQ: IMNM
- Horn Kinney received 31,250 RSUs with a grant price of $0 on July 23, 2026
- Kinney was also granted 62,500 stock options at an exercise price of $22.01 per share on the same date
- RSUs vest over four years at 25% annually; options vest 25% on July 23, 2027, then monthly over the next three years
Restricted Stock Unit Award Details for Immunome’s Chief Business Officer
On July 23, 2026, Horn Kinney, Chief Business Officer at Immunome Inc., was granted 31,250 RSUs as disclosed in the company’s SEC beneficial ownership filing. Each RSU entitles Kinney to one share of common stock upon settlement. The RSUs vest in equal 25% installments annually over four years, contingent on Kinney’s continuous employment. This schedule means Kinney will receive approximately 7,812 shares per year, assuming uninterrupted service.
This four-year vesting timetable is standard among public companies to promote executive retention and long-term commitment. The RSUs were granted without a purchase price, typical for equity awards linked to ongoing employment. Post-grant, Kinney directly owns 31,250 RSUs, fully reflecting the July 23, 2026 award. This vesting structure ensures alignment of executive interests with shareholder value over time.
Stock Options Granted to Kinney with $22.01 Exercise Price
Alongside the RSUs, Kinney received 62,500 employee stock options on July 23, 2026. These options have a $22.01 exercise price and a ten-year expiration date of July 22, 2036. Vesting begins with 25% of the options vesting on July 23, 2027, followed by monthly vesting of the remaining 75% over 36 months, contingent on continuous employment. This equates to about 15,625 shares vesting after one year and roughly 1,302 shares vesting monthly thereafter through July 2030.
The exercise price sets the cost at which Kinney can purchase Immunome shares during the option term. The combination of annual and monthly vesting incentivizes retention and performance over the multi-year period. Kinney now holds 62,500 options subject to these vesting and service conditions.
Immunome’s Executive Compensation and Equity Alignment Strategy
The equity awards to Kinney illustrate Immunome’s compensation approach, blending RSUs and stock options. This dual-grant method balances immediate equity ownership incentives with long-term growth potential. RSUs provide near-term retention benefits through scheduled vesting, while options offer upside tied to stock price appreciation above the $22.01 strike price.
The sizable grants—31,250 RSUs and 62,500 options—reflect Immunome’s commitment to competitive equity compensation for senior management. The Chief Business Officer role, encompassing corporate development and strategic partnerships, warrants substantial equity incentives. The four-year vesting schedules align Kinney’s financial interests with shareholder returns, consistent with governance practices at comparable biopharmaceutical firms.
Beneficial Ownership Update Following July 2026 Grant
Following the July 23, 2026 transaction, Kinney’s beneficial ownership increased by the full amount of the grants. The SEC filing confirms Kinney holds 31,250 RSUs and 62,500 options directly, with no indirect ownership. This disclosure establishes a baseline for future ownership changes. All securities are held directly rather than through trusts or entities.
The grant date coincides with the transaction date, and the filing was submitted on July 27, 2026, within four business days, complying with regulatory timelines. Sandra Stoneman signed the Form 4 as Attorney-in-Fact for Kinney, a common administrative procedure. This filing enhances transparency about executive equity holdings and potential conflicts of interest at Immunome.
Vesting and Service Requirements for Kinney’s Equity Awards
Both RSUs and stock options require Kinney’s continuous employment through each vesting date. RSUs vest annually on the grant anniversary—July 23 of each year from 2027 through 2030—at 25% increments. The options vest 25% on July 23, 2027, with the remainder vesting monthly in equal parts over the next 36 months starting August 2027.
If Kinney’s employment ends before vesting, unvested awards typically forfeit unless accelerated by company policy or agreements, none of which are indicated in the filing. This vesting structure promotes long-term retention and shareholder alignment.
Grant Execution Timeline and Regulatory Filing Compliance
The equity awards were granted on July 23, 2026, the effective date for compensation and vesting. The SEC Form 4 was filed on July 27, 2026, within the four-business-day window, demonstrating compliance with insider reporting rules. No alternative execution date applies, confirming July 23 as the grant date.
Sandra Stoneman’s signature as Attorney-in-Fact authorized the filing. The document includes standard SEC warnings about the accuracy of disclosures, fulfilling Immunome’s public reporting obligations and updating the company’s beneficial ownership records.
Shareholder and Governance Implications of Kinney’s Equity Grant
The large equity grant to Kinney has implications for Immunome shareholders regarding executive compensation and potential dilution. The combined 93,750 securities (RSUs plus options) represent a significant incentive for a senior executive. Shareholders may evaluate whether the grant size aligns with company performance, Kinney’s contributions, and industry standards. The $22.01 option exercise price provides a benchmark for assessing future stock appreciation.
This grant structure aligns Kinney’s interests with shareholders by linking compensation to equity vesting and option exercise. However, the grant’s size may contribute to dilution and warrants monitoring alongside other compensation components. Shareholders may look for additional disclosure in proxy statements or annual reports for comprehensive governance and compensation context.
Regulatory Compliance and Section 16 Reporting Details
The Form 4 filing confirms Immunome’s adherence to Section 16(a) of the Securities Exchange Act of 1934, which mandates timely reporting of ownership changes by officers like Kinney. The filing identifies Kinney as an officer, not a director or 10% owner, and lists the company’s address as 18702 N. Creek Parkway, Suite 100, Bothell, Washington 98011.
The filing certifies that the transaction was not executed under a Rule 10b5-1 trading plan, indicating it was a standard compensation award rather than a pre-arranged sale. This transparency allows investors to monitor insider equity positions and potential conflicts within company leadership.
Context of the Equity Award Within Immunome’s Corporate Framework
Immunome Inc., trading on NASDAQ as IMNM, operates in the biopharmaceutical and immunology sectors. As Chief Business Officer, Kinney likely oversees corporate development, strategic partnerships, and business operations. The substantial equity grant underscores the strategic importance of this role in driving growth and shareholder value in a competitive biotech market.
The filing does not disclose Kinney’s tenure, prior compensation, or relative equity awards to peers, limiting assessment of the grant’s full context. Investors seeking deeper insight should consult Immunome’s annual proxy statements, which provide detailed executive compensation data and peer comparisons. The Form 4 confirms the equity grant but does not offer comprehensive governance or compensation narratives. Future filings may provide additional context on Kinney’s evolving role and compensation philosophy at Immunome.
